In last trading session, Pacific Biosciences of California, Inc. (NASDAQ:PACB) saw 2,990,775 shares changing hands with its beta currently measuring 1.18. Company’s recent per share price level of $13.96 trading at $0.01 or 0.07% at ring of the bell on the day assigns it a market valuation of $2.47 Billion. That closing price of PACB’s stock is at a discount of -0.93% from its 52-week high price of $14.09 and is indicating a premium of 84.24% from its 52-week low price of $2.2. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.18 Million shares which gives us an average trading volume of 3.49 Million if we extend that period to 3-months.
For Pacific Biosciences of California, Inc. (PACB), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.4. Splitting up the data highlights that, out of 5 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.13 in the current quarter.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) trade information
Upright in the green today for gaining 0.07%, in the last five days PACB remained trading in the green while hitting it’s week-highest on Wednesday, Oct 14 when the stock touched $14.09- price level, adding 0.92% to its value on the day. Pacific Biosciences of California, Inc.’s shares saw a change of 171.6% in year-to-date performance and have moved 14.15% in past 5-day. Pacific Biosciences of California, Inc. (NASDAQ:PACB) showed a performance of 92.02% in past 30-days. Number of shares sold short was 17.38 Million shares which calculate 4.98 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $13.2 to the stock, which implies targetted prices is already lagging behind -5.44% to its current value. Analysts have been projecting $7 as a low price target for the stock while placing it at a high target of $17. It follows that stock’s current price would jump +21.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of -49.86% for stock’s current value.
Pacific Biosciences of California, Inc. (PACB) estimates and forecasts
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $20.35 Million for the same. And 4 analysts are in estimates of company making revenue of $26.77 Million in the next quarter that will end in December 01, 2020. Company posted $21.91 Million and $27.93 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -7.1% while estimating it to be -4.2% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.1% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 27.3% while estimates for its earnings growth in next 5 years are of 30%
Pacific Biosciences of California, Inc. (NASDAQ:PACB)’s Major holders
Insiders are in possession of 4.33% of company’s total shares while institution are holding 87.94% percent of that, with stock having share float percentage of 91.93%. Investors also watch the number of corporate investors in a company very closely, which is 205 institutions for Pacific Biosciences of California, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at PACB for having 13.34 Million shares of worth $46.04 Million. And as of June 29, 2020, it was holding 8.64% of the company’s outstanding shares.
The second largest institutional holder is Bellevue Group AG, which was holding about 8.36 Million shares on June 29, 2020. The number of shares represents firm’s hold over 5.42% of outstanding shares, having a total worth of $28.85 Million.
On the other hand, Smallcap World Fund and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 12242300 shares of worth $42.24 Million or 7.93% of the total outstanding shares. The later fund manager was in possession of 9.63 Million shares on July 30, 2020, making its stake of worth around $35.92 Million in the company or a holder of 6.24% of company’s stock.